S ince the exciting findings in the late 1980s and early 1990s that depression predicts prognosis in patients recovering from heart attacks, there has been little substantive advance in the treatment of mood disorders in patients with CHD. Although confirmatory epidemiologic studies have continued to appear (see the summary in the accompanying article by Frasure-Smith and Lespérance, 1), there has been little clinically relevant research. Because most clinical trials of antidepressants have excluded patients with medical comorbidity and because such patients, including those with CHD, often take multiple other medications that can interact with some antidepressants, the existing evidence base for depression treatment does not directly translate to CHD patients.
The landmark ENRICHD Trial (2), funded by the United States National Heart, Lung and Blood Institute between 1996 and 2002, was designed as the first step in improving clinical treatment for post-MI patients suffering from depression. At the same time, the ENRICHD Trial tested the hypothesis that treating depression with CBT, plus an SSRI antidepressant when needed, can improve cardiac prognosis. As summarized in the accompanying article (1), the results were disappointing. The usual care control group received a good deal of cointervention with antidepressants, and although overall differences in changes in depression were statistically significant, they were small. There was no evidence of a difference in cardiac events over the average follow-up period of 29 months. Since the publication of the results in 2003, researchers and clinicians have been wondering what the next step should be. Is it really possible to change depression symptoms in cardiac patients sufficiently to affect either the pathophysiology of cardiac disease or patient compliance with medical treatment and thus save lives?
Imagine, for a moment, that the results of ENRICHD had been positive. What if, in addition to reducing depression symptoms, CBT plus sertraline as needed had resulted in better survival than usual care? Most of us working in behavioural cardiology would be a good deal happier and would probably have been much more productive over the last 3 years. However, what would we have known? We would have had a better idea of how to treat CHD patients suffering from depression, but we would not have known whether reducing depression symptoms per se results in decreased cardiac events. We also would not have known which component of the intervention was crucial for the reduction in cardiac events. This is because, like many other medical treatments, depression treatment-whether by CBT or SSRIs-has pleiotropic effects on body systems other than the brain, including the cardiovascular system. This means that the net effect on cardiac outcomes of any treatment for depression is likely to be at least as much a function of the sum of its impact on the cardiovascular mechanisms linking depression with prognosis as a function of its impact on depressive symptoms per se. As summarized in the accompanying review by Skala, Freedland, and Carney (3), in addition to the behavioural mechanism of adherence to medical advice and risk factor modification, there are reasonable data supporting that 5 biological mechanisms are involved in the link between depression and CHD: exaggerated platelet activation (4-7); reduced heart rate variability, reflecting increased sympathetic activity and (or) reduced vagal activity (8) ; increased innate inflammatory response (9,10); endothelial dysfunction (11, 12) ; and reduced levels of omega-3 free fatty acids (13, 14) . It is plausible that antidepressants have some effects on several of these mechanisms. However, it is also important to understand that an effective antidepressant agent may even have a negative effect on cardiac outcomes. For example, tricyclic antidepressants have been shown to increase norepinephrine turnover (15) and increase the risk of ventricular arrhythmias (16) , making them contraindicated in cardiac patients. Beyond the data on tricyclics, there has been little mechanistic research on the cardiovascular impact of antidepressants. However, some data suggest that SSRIs have antiplatelet effects (17) . In addition, SSRIs have been shown to improve markers of endothelial function in humans (18) . Although lower heart rate variability is the best-supported mechanism linking depression and cardiac prognosis (8) , SSRIs seem to have little impact on it (19) . Finally, while animal research suggests that antidepressants have an effect on inflammation (20, 21) , relatively little is known about the influence of SSRIs and other newer antidepressants on the regulation of inflammation in humans. However, one recent study intriguingly demonstrated that SSRIs reduce C-reactive protein levels in patients with major depression, independent of their impact on depression symptoms (22) . Therefore, the net effect of a specific treatment would be the sum of its effects on these cardiovascular mechanisms and on others not yet discovered, in addition to its impact on behaviour.
To design randomized trials aimed at reducing the negative prognostic impact of depression and improving our evidence base for the clinical care of CHD patients with depression, it would make sense to use interventions that not only improve depressive symptoms but also, more importantly, target several of the mechanisms thought to causally link depression to cardiac events. In particular, we believe that investigators will need to give serious consideration to testing the beneficial impact of aerobic exercise and omega-3 fatty acids. There is some evidence that, in addition to their possible antidepressant properties, both of these treatments have positive effects on inflammation, heart rate variability, and endothelial function (23) (24) (25) (26) (27) (28) (29) (30) (31) . Interestingly, recent clinical research has shown antidepressant properties of a potent inhibitor of proinflammatory cytokines, opening a new paradigm for the treatment of depression (32) .
Trials of depression treatments with pleiotropic cardiovascular effects have the potential to improve clinical care and patient prognosis but will not necessarily help us prove that it is the changes in depression that lead to improved cardiac outcomes. Does it matter? The only way to prove that changing depression causes a change in cardiac events would be to use a treatment without pleiotropic effects. Such an agent is unlikely to exist. Given the complexities of the multiple body systems linking the brain and the heart, that goal has in fact probably always been far too simplistic. Our pursuit of it may prove to be reminiscent of Don Quixote and his windmills. It is time to refocus our research efforts on improving the clinical treatment of both depression and CHD in CHD patients with depression.
